Soleno Therapeutics (NASDAQ:SLNO) issued its quarterly earnings data on Wednesday. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.08), Bloomberg Earnings reports.
Soleno Therapeutics opened at $1.85 on Friday, according to MarketBeat. Soleno Therapeutics has a 52 week low of $1.76 and a 52 week high of $1.77.
In other news, major shareholder Larry N. Feinberg bought 50,000 shares of Soleno Therapeutics stock in a transaction that occurred on Tuesday, May 15th. The shares were acquired at an average price of $1.80 per share, with a total value of $90,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 69.75% of the stock is owned by corporate insiders.
Soleno Therapeutics Company Profile
Soleno Therapeutics, Inc focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, diazoxide choline controlled-release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is entering into Phase II/III clinical development.
Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.